Quick Answer
Sana Biotechnology, Inc. reported Net Income of -$244.17 million for fiscal year 2025.
Sana Biotechnology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$244.17M +8.5% |
-$266.76M +5.8% |
-$283.25M -5.1% |
-$269.48M +24.3% |
-$355.93M -24.8% |
-$285.31M -118.2% |
| Diluted EPS | -$0.96 +17.2% |
-$1.16 +20.5% |
-$1.46 -2.1% |
-$1.43 +33.2% |
-$2.14 +90.2% |
-$21.92 |
| Total Assets | $416.89M -16.8% |
$501.02M -11.4% |
$565.30M -31.3% |
$822.72M -27.2% |
$1.13B +54.7% |
$730.30M |
| Cash and Equivalents | $71.87M -43.7% |
$127.57M -4.5% |
$133.52M -24.5% |
$176.76M -30.1% |
$253.03M +102.7% |
$124.81M |
| Stockholders Equity | $160.88M -35.8% |
$250.50M -12.9% |
$287.51M -42.4% |
$499.31M -31.5% |
$728.50M +273.0% |
-$421.18M -195.5% |
| R&D Expense | $131.98M -38.8% |
$215.67M -17.6% |
$261.81M -8.4% |
$285.88M +15.0% |
$248.63M +87.0% |
$132.94M +33.5% |
| Operating Income | -$250.32M +8.2% |
-$272.72M +7.0% |
-$293.14M -7.5% |
-$272.56M +23.6% |
-$356.91M -24.7% |
-$286.15M -102.7% |
| Shares Outstanding | 266.73M +19.1% |
223.92M +13.2% |
197.86M +3.6% |
191.02M +3.3% |
184.93M +1043.7% |
16.17M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$42.15M | +29.7% | +55.1% |
| Diluted EPS | September 30, 2025 | -$0.16 | +36.0% | +59.0% |
| Total Assets | September 30, 2025 | $435.43M | -22.2% | +20.4% |
| Cash and Equivalents | September 30, 2025 | $103.36M | -18.6% | +45.0% |
| Stockholders Equity | September 30, 2025 | $195.31M | -33.2% | +59.4% |
| R&D Expense | September 30, 2025 | $30.11M | -43.4% | +1.2% |
| Operating Income | September 30, 2025 | -$43.52M | +29.5% | +54.2% |
| Shares Outstanding | September 30, 2025 | 262.26M | +17.6% | +13.8% |
- Sana Biotechnology, Inc. reported Net Income of -$244.17 million for fiscal year 2025.
- Sana Biotechnology, Inc. showed an increase of +8.5% in Net Income compared to the prior fiscal year.
- Sana Biotechnology, Inc. reported Diluted EPS of $0.96 per share (loss) for fiscal year 2025.
- Sana Biotechnology, Inc. showed an increase of +17.2% in Diluted EPS compared to the prior fiscal year.
- Sana Biotechnology, Inc. reported Total Assets of $416.89 million for fiscal year 2025.
- Sana Biotechnology, Inc. showed a decrease of -16.8% in Total Assets compared to the prior fiscal year.
- Sana Biotechnology, Inc. reported Cash and Equivalents of $71.87 million for fiscal year 2025.
- Sana Biotechnology, Inc. showed a decrease of -43.7% in Cash and Equivalents compared to the prior fiscal year.
- Sana Biotechnology, Inc. reported Stockholders Equity of $160.88 million for fiscal year 2025.
- Sana Biotechnology, Inc. showed a decrease of -35.8% in Stockholders Equity compared to the prior fiscal year.
- Sana Biotechnology, Inc. reported R&D Expense of $131.98 million for fiscal year 2025.
- Sana Biotechnology, Inc. showed a decrease of -38.8% in R&D Expense compared to the prior fiscal year.
- Sana Biotechnology, Inc. reported Operating Income of -$250.32 million for fiscal year 2025.
- Sana Biotechnology, Inc. showed an increase of +8.2% in Operating Income compared to the prior fiscal year.
- Sana Biotechnology, Inc. reported Shares Outstanding of 266.73 million shares for fiscal year 2025.
- Sana Biotechnology, Inc. showed an increase of +19.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: